Viridian Shares Fall 25% After Amgen Data

Viridian Therapeutics stock plunged 25.2% on Monday following Amgen’s positive Phase 3 TEPEZZA on‑body injector trial results.
Amgen’s TEPEZZA OBI achieved a 77% proptosis response versus 19.6% placebo over 24 weeks, surpassing Viridian’s elegrobart data.
TEPEZZA OBI’s absolute response was 76.7% versus 54% (Q4W) and 63% (Q8W) for elegrobart, with placebo‑adjusted gaps of 57% vs 36%/45%.
Analysts kept Viridian ratings: Stifel’s Alex Thompson Buy $48, RBC’s Lisa Walter Outperform $42, Leerink’s Thomas Smith Outperform $50.